Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes

Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes

Background: Tigecycline is a therapeutic option for carbapenemase-producing <i>Klebsiella pneumoniae</i> (CP-Kp). Our aim was to evaluate the impact of the tigecycline’s minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp bacteraemia treated with tigecycline mono...

Full description

Bibliographic Details
Main Authors: Matthaios Papadimitriou-Olivgeris, Christina Bartzavali, Alexandra Nikolopoulou, Fevronia Kolonitsiou, Virginia Mplani, Iris Spiliopoulou, Myrto Christofidou, Fotini Fligou, Markos Marangos
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Antibiotics
Subjects:
tigecycline
bloodstream infection
carbapenemase
carbapenem-resistance
ceftazidime/avibactam
colistin
Online Access:https://www.mdpi.com/2079-6382/9/11/828

Internet

https://www.mdpi.com/2079-6382/9/11/828

Similar Items